S. Giannini et al., BONE-DENSITY AND MINERAL METABOLISM IN THYROIDECTOMIZED PATIENTS TREATED WITH LONG-TERM L-THYROXINE, Clinical science, 87(5), 1994, pp. 593-597
1. A decreased bone mass has been reported in patients with endogenous
hyperthyroidism, but the effect on bone density and mineral metabolis
m of thyroxine administration in thyroidectomized patients is still co
ntroversial. To further contribute to this debate, we studied 25 women
thyroidectomized for thyroid cancer on long-term treatment with thyro
id-stimulating hormone-suppressive doses of L-thyroxine. Twenty-one se
x- and age-matched normal subjects were also studied as a control grou
p. 2. The bone density of the spine and serum calcitonin, calcitriol a
nd parathyroid hormone concentrations were not different when the whol
e patient group was compared with the control subjects, nor when the p
atients and central subjects were compared according to their menopaus
al status. However, postmenopausal thyroidectomized patients showed si
gnificantly lower bone mass (P < 0.001) than premenopausal patients. 3
. L-Thyroxine-treated patients showed significantly higher levels of b
one alkaline phosphatase and urine hydroxyproline excretion than contr
ol subjects (P < 0.003 and P < 0.001, respectively). These differences
were still present when patients and control subjects were analysed a
ccording to their menopausal status. However, bone alkaline phosphatas
e was significantly higher in postmenopausal than in premenopausal wom
en only in L-thyroxine-treated patients (P < 0.05). In postmenopausal
L-thyroxine-treated patients a negative correlation between time since
menopause and bone mass (P < 0.05) and a positive correlation between
bone alkaline phosphatase and hydroxyproline excretion (P < 0.03) wer
e also found. 4. We conclude that long-term thyroid-stimulating hormon
e-suppressive treatment with L-thyroxine in thyroidectomized women is
not associated with a decrease in spinal bone mass nor with calcitonin
deficiency, and that L-thyroxine treatment may increase skeletal sens
itivity to menopause-related bone loss.